Age-Related Characteristics of Multipotent Human Nasal Inferior Turbinate-Derived Mesenchymal Stem Cells

Abstract

Background and ObjectivesMultipotent mesenchymal stem cells (MSCs) represent a promising cell-based therapy for a number of degenerative conditions. Understanding the effect of aging on MSCs is crucial for both autologous therapy development and allogenic donors in older subjects whom degenerative diseases typically afflict. In this study, we investigated the influence of donor age on the characteristics, proliferation, and differentiation potential of in vitro cultures of multipotent human turbinated mesenchymal stem cells (hTMSCs) from patients of various age groups.Subjects and MethodsTwelve patients comprised the four age groups: (I) <20 years, (II) 20–39 years, (III) 40–59 years, and (IV) >60 years. Inferior turbinate tissues were discarded from patients undergoing partial turbinectomy. After isolating hTMSCs, the expression of the hTMSC surface markers CD14, CD19, CD34, CD73, CD90, CD105, and HLA-DR was assessed by FACS analysis, and cell proliferation was assessed using a cell counting kit (CCK)-8. The differentiation potential of hTMSCs was evaluated in osteogenic media by histology and determination of osteoblastic gene expression.ResultsFACS analysis revealed that hTMSCs were negative for CD14, CD19, CD34, and HLA-DR, and positive for CD73, CD90, and CD105, representing a characteristic MSC phenotype, and showed no significant differences among the age groups. Cellular proliferation and osteogenic differentiation potential of hTMSCs also showed no significant differences among the age groups.ConclusionsWe conclude that donor age does not affect the characteristics, proliferation, and osteogenic differentiation potential of hTMSCs. Donor age may be excluded as a criterion in the guidelines for clinical use of the autologous or allogenic transplantation of hTMSCs.

Human Turbinate-derived Mesenchymal Stem Cells Differentiated into Keratocyte Progenitor Cells

“…hTMSCs were negative for hematopoietic markers CD14, CD19, CD34 and HLA-DR, and positive for MSC markers CD73, CD90 and CD105. This result indicates that 14 d of differentiation does not affect multipotent ability of hTMSCs (Figure 3) [23].…”

“…MSCs are widely used in cell-based therapy due to their facile isolation and multipotent capacity including proliferation compared to other adult stem cell [23,33]. However, cell-based therapy for keratocyte has severe limitations because keratocytes easily transform to fibroblast that secrete metalloproteinase that induces extracellular remodeling in vivo and in vitro.…”

“…Fresh turbinate mesenchymal stem cells were obtained from patients who had undergone partial turbinectomy at the Catholic University of Korea, St. Mary's Hospital [23,24]. The protocols of this study were approved by the Internal Review Board for Human Subjects Research and Ethics Committee (KC08TISS0341), and informed consent was acquired from each patient before enrollment in this experiment.…”

“…hTMSCs are located in the interior of turbinate; they are easy to reach, and have high proliferation competence, relatively high yield and prolonged efficacy [23]. hTMSCs have been used in cell therapy for chondrogenic [23,24], osteogenic [23][24][25][26], adipogenic [24], neurogenic [24] and tracheal epithelial differentiation [27].…”

“…hTMSCs have been used in cell therapy for chondrogenic [23,24], osteogenic [23][24][25][26], adipogenic [24], neurogenic [24] and tracheal epithelial differentiation [27]. Characteristics of hTMSCs do not differ significantly between patients under 20 years old and patients in their 40s or 50s [23], but the ability of hTMSCs to differentiate into keratocyte progenitor like cells has never been demonstrated. Thus, this study first reveal the differentiation of hTMSCs into keratocyte progenitor like cells.…”